Morgan Stanley has a team of investors and researchers tasked with identifying the next “big idea that has the potential to trigger far-reaching consequences.” The team, operating under the name Counterpoint Global, has now profiled psychedelics in a four-page viewpoint piece ( PDF). Operating under the Morgan Stanley Investment Management (MSIM) banner, Counterpoint is a fundamental equity team…

Source

Previous articleatai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
Next articleatai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update